The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large A… (NCT06757764) | Clinical Trial Compass
RecruitingPhase 4
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
South Korea2,340 participantsStarted 2025-07-10
Plain-language summary
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
Who can participate
Age range20 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age of 20 years or older
✓. Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography.
✓. Informed consent obtained within 72h from stroke onset
✓. Acquisition of written informed consent prior to study entry
Exclusion criteria
✕. Large infarction unable to start antiplatelet treatment
✕. Combined with acute intracranial haemorrhage
✕. With initial haemorrhagic transformation
✕. Previous mRS higher than 2
✕. Indicated for anticoagulation
✕
What they're measuring
1
Proportion of occurrence of composite endpoint
Timeframe: during admission (within 14 days) and within 180 days after stroke